FDA product code GKA: Abnormal Hemoglobin Quantitation
GKA is the FDA product code for abnormal hemoglobin quantitation. It is a Class II device, regulated under 21 CFR 864.7415 and reviewed by the Hematology panel. FDA has cleared 23 510(k) submissions under GKA, 3 in the last five years, from 13 different applicants. The average 510(k) review took 194 days (median 129); 272 days on average over the last three years. FDA has posted 10 recalls for GKA devices, 1 initiated in the last five years.
Classification
| Field | Value |
|---|---|
| Device name | Abnormal Hemoglobin Quantitation |
| Device class | Class II |
| Regulation | 21 CFR 864.7415 |
| Review panel | HE — Hematology |
| Medical specialty | Hematology |
| Premarket route | 510(k) |
| Third-party 510(k) review eligible | Yes |
510(k) clearances per year for GKA
| Year | Clearances | Avg. review days |
|---|---|---|
| 2017 | 1 | 100 |
| 2018 | 1 | 266 |
| 2022 | 1 | 915 |
| 2023 | 1 | 338 |
| 2024 | 1 | 272 |
Compare with all 510(k) review times · Search every GKA clearance
Top GKA applicants
| Applicant | Clearances | Latest |
|---|---|---|
| Sebia | 7 | 2024-04-04 |
| Bio-Rad | 3 | 1996-04-26 |
| Bio-Rad Laboratories, Inc. | 2 | 2017-09-13 |
| Helena Laboratories | 2 | 1982-08-05 |
| Trinity Biotech (Primus Corporation, Dba Trinity Biotech) | 1 | 2023-08-04 |
8 more applicants have GKA clearances. See the full list in Caduvo.
Most recent GKA clearances
| 510(k) | Applicant | Device | Decision date | Review days |
|---|---|---|---|---|
| K232027 | Sebia | CAPI 3 NEONAT Hb, CAPILLARYS 3 DBS Instrument | 2024-04-04 | 272 |
| K222635 | Trinity Biotech (Primus Corporation, Dba Trinity Biotech) | Premier Resolution System | 2023-08-04 | 338 |
| K192931 | Helena Laboratories, Corp. | V8 Nexus Hemoglobin Ultrascreen, V8 AFSA2 Hemo Control | 2022-04-19 | 915 |
| K180762 | Sebia | CAPI 3 HEMOGLOBIN(E) | 2018-12-14 | 266 |
| K171664 | Bio-Rad Laboratories, Inc. | Hemoglobin Variants System on Newborn Hemoglobin System with GDM and HbReview Software | 2017-09-13 | 100 |
Recalls for GKA devices
10 product recalls in 6 recall events; 1 initiated in the last five years and 1 still open. Most recent: 2022-04-07.
| Year | Recalls |
|---|---|
| 2018 | 5 |
| 2020 | 1 |
| 2022 | 1 |
Frequently asked questions
What is FDA product code GKA?
GKA is the FDA product code for abnormal hemoglobin quantitation. It is a Class II device, regulated under 21 CFR 864.7415 and reviewed by the Hematology panel.
What device class is GKA?
Class II, regulation 21 CFR 864.7415. Typical premarket route: 510(k).
How long does a 510(k) take for product code GKA?
Across 23 cleared submissions the average was 194 days from receipt to decision (median 129).
Which companies have the most GKA clearances?
Sebia (7); Bio-Rad (3); Bio-Rad Laboratories, Inc. (2); Helena Laboratories (2); Trinity Biotech (Primus Corporation, Dba Trinity Biotech) (1).
Have GKA devices been recalled?
Yes: 10 product recalls across 6 recall events; the most recent began 2022-04-07.
Next steps
- Run an FDA pathway report with predicate devices for product code GKA
- Run a recall and safety report across every GKA manufacturer
- Watch product code GKA for new clearances and recalls
Compiled by Caduvo from public U.S. FDA records. Applicant names are shown as FDA records them. Review days run from FDA receipt to decision. Not reviewed or endorsed by FDA. Not regulatory advice. Report an error. Data and corrections policy.
All Hematology product codes · FDA product code lookup · 510(k) database search · 510(k) review times